A 24-month study in Kenya, Uganda and South Africa has found that injectable HIV treatment, Cabotegravir/Rilpivirine, also known in medical terms as CAB LA + RPV LA, administered every two months, is safe, well-tolerated, and preferred by most HIV patients.
Fact‑first reporting that puts you at the heart of the newsroom. Subscribe for full access.
- Unlimited access to all premium content
- Uninterrupted ad-free browsing experience
- Mobile-optimized reading experience
- Weekly Newsletters
- MPesa, Airtel Money and Cards accepted